A new wave of 2026 research from Stanford, Harvard, and the Karolinska Institutet is rewriting what the vagus nerve does and how simple breathing practices can tune it. Here is…
New 2026 research is reshaping longevity medicine through the gut. From Kenya Honda’s discovery of isoalloLCA in Japanese centenarians, to Patrice Cani’s Akkermansia muciniphila trials at UCLouvain, to the ARMOR…
💪 ACSM Rewrites Resistance Training Guidelines: New evidence confirms that any amount of resistance training builds strength and muscle, even bodyweight exercises at home, with consistency mattering far more than complexity. ❤️ CRISPR Infusion Cuts Cholesterol by 50%: A single gene editing infusion safely halved LDL cholesterol in 15 adults, bringing one-time cardiovascular interventions closer to the clinic. 🦠 Housemates Shape Your Gut Microbiome: New research shows that daily physical interactions with the people you live with drive microbial exchange, regardless of shared diet. 🔬 First Epigenetic Reprogramming Therapy Enters Human Trials: The FDA cleared ER-100, the first partial reprogramming therapy to reach clinical testing, targeting optic neuropathies with cellular rejuvenation. 🧠 FTL1 Protein Drives Brain Aging: Scientists identified a specific protein whose reduction in older mice restored synaptic function and improved memory, opening a new therapeutic avenue for cognitive preservation.
Scientists at the 2nd World Congress on Targeting Longevity in Berlin delivered an uncomfortable verdict in April 2026: despite decades of discoveries, longevity science has stalled on clinical translation. The…
New 2026 research on myokines, the signaling proteins released by contracting muscle, shows why strength training is a cognitive intervention. Here is what the science reveals about irisin, cathepsin B,…
Ray Kurzweil has spent two decades arguing that by 2029, medical progress will add more than a year to your remaining life expectancy for every year that passes. A Nobel-laureate…
For four decades, a single protein drove roughly a third of all human cancers, and nobody could build a drug against it. Here is why that story is finally changing,…
Five Nobel laureates are quietly orbiting Isomorphic Labs, the Alphabet-backed company trying to use artificial intelligence to end the world’s deadliest diseases. What they are building would have been science…
For decades, cardiac amyloidosis was a diagnosis cardiologists whispered and patients rarely heard. In 2026, tafamidis, acoramidis, RNA silencers, and a CRISPR gene editing therapy are transforming ATTR care and…
New glymphatic research reveals that deep slow wave sleep drives the brain’s nightly clearance of amyloid and tau, with 2026 data linking sleep architecture to long term dementia risk and…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.